ClinicalTrials.gg
TerminatedNCT05518344Updated Aug 26, 2022

Study of Viziatek ISL™ Refractive Phakic Intra Sulcus Lens for Refraction Adjustment in Blind Volunteers

An interventional study of Viziatek ISL™ (hereinafter referred to as the "ISL") implanted in blind eye. in Myopia, sponsored by Hanita Lenses. Terminated at 1 site in Latvia. Per ClinicalTrials.gov, last updated 2022-08-26.

Sponsored by Hanita Lenses · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor decision to terminate the study

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jun 2020, registered Mar 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Sex
All
01

Study summary

This is a clinical investigation. A total of up to 5 subjects, but not less than 3 at one investigational site will undergo insertion of the ISL in one eye and will be followed through 6 months postoperative.

Subjects from the United States will not be enrolled in this study.

Read the detailed description

The Viziatek ISL is intended to improve myopic vision and decrease dependence on glasses in myopic adults who don't have an irregular astigmatic cornea (as evaluated by topography), who require correction of -3.50 D to -23 D, who have BCVA - Distance between 20/20 to 20/30 and with no more than 5 D of the refractive cylinder, and who have stable MRSE within 0.50 D over the past 12 months.

02

Conditions studied

  • Myopia

Browse trials for

03

In context

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

This study's enrollment of 4 is below the median of 79 across 929 interventional studies indexed under Myopia.

Browse Myopia studies →

Lead sponsor

Hanita Lenses is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must sign and be given a copy of the signed Form (ICF).
  2. Subjects must be legally blind.
  3. Subjects must have best-corrected distance visual acuity of 20/400 or worse.
  4. Subjects must have an endothelial cell count ≥ 1800 cells/mm2 in the eye to be implanted.
  5. Subjects must have a photopic pupil size of > 2 mm in the eye to be implanted.
  6. Anterior chamber depth (ACD) ≥ 2.8 mm
  7. Anterior chamber angle ≥ Grade III
  8. Subjects must be willing and able to return for scheduled follow-up examinations for 12 months after surgery if asked.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have best-corrected visual acuity of better than 20/400
  2. Subjects with anterior segment pathology, including cataracts, in either eye.
  3. Subjects with residual, recurrent, active ocular or uncontrolled eyelid disease or any progressive corneal abnormalities (including endothelial dystrophy, guttate in the central cornea, etc.) in the eye to be treated.
  4. Subjects with a history of the chronic dry eye not controlled on therapy or with superficial punctuate keratitis (SPK) grade > II (i.e., greater than mild) based on Oxford Grading Scale12 in the eye to be treated.
  5. Subjects who have undergone previous intraocular or corneal surgery including cataract and refractive surgery (e.g., LASIK surgery) in either eye.
  6. Subjects using ophthalmic medication(s) other than artificial tears for treatment of ocular pathology.
  7. Subjects with a history of disease, connective tissue disease, or clinically significant atopic syndrome.
  8. Subjects with a history of herpes zoster or herpes simplex keratitis.
  9. Subjects with a history of a -responsive rise in intraocular pressure (IOP), or a preoperative IOP > 21 mmHg or glaucoma.
  10. Subjects with distorted, non-reactive, or decentered pupils.
  11. Subjects on chronic systemic or topical corticosteroids or other therapy that may affect wound healing, and any immuno-compromised subjects (use of intranasal steroids for seasonal allergies are acceptable).
  12. Subjects using systemic medications with significant ocular side effects.
  13. Subjects who are pregnant or are considering becoming pregnant during the time of the study.
  14. Subjects with known sensitivity to planned study concomitant medications.
  15. Subjects who are participating in any other drug or device clinical investigation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    single arm

    * Release ISL from Inserter * Remove Inserter. * Tack the haptics under the iris in 4 locations * Verify that ISL is centered * Remove lid speculum and drape from subject's eye and face. * Move the subject to a slit lamp and verify ISL centration.

    Device: Viziatek ISL™ (hereinafter referred to as the "ISL") implanted in blind eye.

Interventions

  • DeviceViziatek ISL™ (hereinafter referred to as the "ISL") implanted in blind eye.

    Viziatek ISL™ (hereinafter referred to as the "ISL") implanted in blind eye.

06

What researchers measure

Primary outcomes

  1. Endothelial cell loss

    Endothelial cell loss in operated eye measured at months 6, and change in cell count from baseline less than 10%.

    Time frame: 6 months

Secondary outcomes

  1. Ultrasound Biomicroscopy (UBM)

    All patients will undergo measurement of the central distance between implanted lens and anterior capsule to be greater than 50 microns (µm)

    Time frame: 6 months

Other outcomes

  1. Slit Lamp Examination

    This includes measurement of aqueous cell and flare by a standard grading system and an evaluation for presence of corneal abnormalities; pupillary irregularities; iris atrophy and pigment dispersion

    Time frame: 6 months

  2. Pupillometry

    Pupil diameter in bright light (photopic condition): 2-4 mm Pupil diameter in the dark (mesopic/scotopic conditions): 4-8 mm The pupils are generally equal in size. Pupil diameter is measured by digital pupilometer that measures distance between the center of each pupil.

    Time frame: 6 months

  3. Keratometry

    Measurement of the power of the cornea

    Time frame: 6 months

  4. Best corrected Visual Acuity

    Measurement by looking at ETDRS Chart with glasses

    Time frame: 6 months

07

Study locations

1 site
  • Drsolomatinisilmakeskus
    Riga, Latvia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Mar 2022, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2021
First posted
Aug 26, 2022
StartActual
Jun 4, 2020
Primary completionActual
Mar 16, 2022
CompletionActual
Mar 16, 2022
Last update
Aug 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05518344
Lead sponsor
Hanita Lenses
Responsible party
Sponsor
First posted
Aug 26, 2022
Start date
Jun 4, 2020
Primary completion
Mar 16, 2022
Completion
Mar 16, 2022
Last update
Aug 26, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion